Colony Group’s Heron Therapeutics HRTX Stock Holding History

Colony Group’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-143	Closed	-$3K	–	830
2015 Q3	$3K	Hold	143	–	–	﹤0.01%	735
2015 Q2	$4K	Hold	143	–	–	﹤0.01%	666
2015 Q1	$2K	Hold	143	–	–	﹤0.01%	673
2014 Q4	$1K	Hold	143	–	–	﹤0.01%	720
2014 Q3	$1K	Hold	143	–	–	﹤0.01%	756
2014 Q2	$2K	Hold	143	–	–	﹤0.01%	670
2014 Q1	$2K	Buy	+143	New	+$1.91K	﹤0.01%	759

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Colony Group's HRTX Position: Q4 2015 in Review

Colony Group sold out of Heron Therapeutics (HRTX) in Q4 2015, closing a stake of 143 shares — an estimated $3K sold.

Colony Group first reported a position in HRTX in Q1 2014 and held it in 7 quarters. The position peaked at $4K in Q2 2015. 107 funds tracked by Wall St. Rank hold HRTX as of Q4 2015.

Colony Group reported no remaining Heron Therapeutics position as of Q4 2015 after selling out during the quarter.
Colony Group sold 143 Heron Therapeutics shares in Q4 2015, an estimated $3K.
Colony Group first reported a position in Heron Therapeutics in Q1 2014 and held it in 7 quarters.
Colony Group's Heron Therapeutics position peaked at $4K in Q2 2015.
107 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2015.

Based on Colony Group's 13F filing for Q4 2015, filed 19 Feb 2016.